AI Article Synopsis
- There has been a resurgence in the interest of therapeutic peptides as potential drug candidates, moving past a period of neglect due to their challenges with metabolism and bioavailability.
- New strategies are being developed to improve the effectiveness of peptide-based drugs, leading to a variety of these drugs being marketed for different medical conditions.
- Although promising results have been found in mouse models for treating autoimmunity, only a few clinical trials are ongoing; one notable peptide, P140/Lupuzor, has successfully completed several phases of clinical trials for systemic lupus erythematosus.
Article Abstract
After a long period where the potential of therapeutic peptides was let into oblivion and even dismissed, there is a revival of interest in peptides as potential drug candidates. Novel strategies for limiting metabolism and improve their bioavailability, and alternative routes of administration have emerged. This resulted in a large number of peptide-based drugs that are now being marketed in different indications. Regarding autoimmunity, successful data have been reported in numerous mouse models of autoimmune inflammation, yet relatively few clinical trials based on synthetic peptides are currently underway. This review reports on peptides that show much promises in appropriate mouse models of autoimmunity and describes in more detail clinical trials based on peptides for treating autoimmune patients. A particular emphasis is given to the 21-mer peptide P140/Lupuzor that has completed successfully phase I, phase IIa and phase IIb clinical trials for systemic lupus erythematosus.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaut.2012.05.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!